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Abstract
Background: Atypical polypoid adenomyoma (APA) is a rare uterine tumor typically found in fertile age and associated with
infertility. Among young nullipara women, conservative treatment is proposed despite the high recurrence rate and the association
with endometrial cancer.
Our aimwas to assess the risk of recurrence with different conservative treatments in fertile ages and the prevalence of malignant or
pre-malignant associated lesions to better address an adequate patient counselling when treatment modalities are discussed.
Methods:This study is a systematic review andmeta-analysis of case reports and case series about APAmanagement and follow-
up. A literature search was carried from Medline and Scopus for studies published from January 1, 1980 to December 31, 2018.
Results:We included 46 observational studies and 296 cases in fertile women. The prevalence of APA relapse was 44% (CI.95 33–
57%) and was lower in cases treated with operative hysteroscopy (22%; CI.95 11–39%) than in cases treated with blind curettage
and polypectomy (38%; CI.95 15–67%). The prevalence of the concomitant or during the follow-up diagnosis of endometrial
carcinoma was 16% (CI.95 9–29%). The risk of cancer development during follow-up was significantly less in cases treated with
histeroscopy (10.56% new cumulative diagnosis at 5 years follow up; CI.95 0–23.7%) than blind curettage and polypectomy (35.5%
new cumulative diagnosis at 5 years; CI.95 11.65–52.92%; P< .05). Medical treatment with medroxyprogesterone acetate after
surgery does not reduce APA recurrence. Pregnancy was observed in 79% cases in which the desire was expressed.
Conclusion:This review suggests that conservative treatment performed by operative hysteroscopy is the optimal choice because
it lowers the risk of recurrence, improves the accuracy of concomitant carcinoma or hyperplasia diagnosis, and leaves the possibility
of future pregnancies.
Abbreviations: APA = atypical polypoid adenomyoma, BMI = body mass index, CI.95 = 95% confidence interval, DCP =
dilatation, curettage and polypectomy, IQR = interquartile range, IUD = intrauterine device, MPA = medroxyprogesterone acetate.
Keywords: atypical polypoid adenomyoma, endometrial cancer, eneometrial hyperplasia, fertility sparing treatment, operative
hysteroscopy
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Highlights - Whats this paper adds
 Conservative treatment of atypical polypoid adeno-
myoma performed by operative histeroscopy is the
optimal choice because it lowers the risk of recurrences.
 Operative histeroscopy improve the accuracy of concom-
itant carcinoma or hyperplasia diagnosis.
 The medical treatment with medroxy progesterone
acetate, following conservative surgery, does not appear
to be beneficial in reducing atypical polypoid adeno-
myoma recurrences.
 The persistence/recurrence of atypical polypoid adeno-
myoma at 10 years follow up was 59.54% (CI.95: 32.88–
75.61%).
 Concomitant diagnosis alone of endometrial carcinoma
was 11% (CI.95 7–17%) and endometrial carcinoma
during follow up was 14% (CI.95 7–26%), and the time-
to-event cumulative events were 59.91% (CI.95: 29.54–
77.19%) at 14 years of follow-up.
1. Introduction
Atypical polypoid adenomyoma (APA) is a rare uterine tumor
composed of atypical endometrial glands surrounded by smooth
muscle tissue bundles. It is intended as benign epithelial and
mesenchymal neoplasm, but it can lead to diagnostic difficulties
given the degree of atypia that distinguishes it. The term APAwas
introduced byMazur in 1981 which described 5 polypoid lesions
in premenopausal women characterized by atypical glands with
squamous metaplasia and a smooth cellular muscle stroma,
previously classified differently from other authors.[1] At an
initial assessment, the picture may appear as adenocarcinoma or
mixed Mullerian tumor, and the diagnosis may be complex in
some cases.[1]
APA is a rare disease, there are <500 cases reported in the
literature and therefore it is difficult to evaluate its incidence.
Typically it is found in fertile age, but some cases are described
also in post-menopausal period.[2,3] In most cases patients
present with abnormal uterine bleeding, menometrorrhagia, or
with anemia.[4] The diagnosis of APA is essentially histological
and it is often macroscopically and clinically indistinguishable
from endometrial polyp, submucous myoma, or adenofi-
broma.
In most cases it is found in young women with possible
associated infertility. Therefore, conservative treatment has been
considered as a valid choice, but recurrences are common as well
as the coexistence or development of atypical endometrial
hyperplasia or endometrial cancer. The origin for the majority of
APA cases (80%) is recognized at the cervical/isthmus level but it
can originate in all uterine portions.[5]
Because APA is rare pathology and affected cases are often
presented as single case or small series, aggregation of these cases
by systematic review and meta-analysis may help to understand
its appropriate clinical management.[6–8]
The underlying question guiding this review was if the
conservative management of APA is a safe procedure in women
of childbearing age with pregnancy desires. Accordingly, we
performed a meta-analysis to assess the concomitancy (or new
diagnosis during follow up) of pre-malignant or malignant lesion,
and recurrences consequent to different APA clinical manage-
ments (Supplemental Table 1, http://links.lww.com/MD/E410).
2. Materials and methods
This study is a systematic review and meta-analysis of case
reports and case series about APAmanagement and follow-up. In
addition, the PRISMA guidelines (Preferred Reporting Items for
Systematic Reviews and Meta-Analyzes) were followed for the
drafting of this meta-analysis.[9]
2.1. Search strategy for review
A literature search was independently carried out by 2 authors
(AB and APL). All information was gathered from Medline and
Scopus for studies published from January 1, 1980 to December
31, 2018 (by online search engines). The following query was
used to search the Medline/PubMed database: “atypical[All
Fields] AND polypoid[All Fields] AND (”adenomyoma“[MeSH
Terms] OR ”adenomyoma“[All Fields])”; while Scopus was
queried using the following strategy: “TITLE-ABS-KEY (atypical
AND polypoid AND adenomyoma).” Meta-information, titles,
and abstracts resulted from these queries were examined. All
articles that referred to APA management were selected and full
texts were searched and analyzed. Eventually, bibliographies and
citations from Scopus items, previous review publications, and
full articles were used to identify other potentially relevant
articles.
2.2. Eligibility criteria, study selection, and data collection
process
All studies that evaluated management in patients affected by
APAwere considered. Only studies about women of childbearing
age presenting information on management and follow-up
concerning relapses, diagnosis of endometrial hyperplasia,
diagnosis of endometrial cancer, and pregnancy were included.
In addition, only studies performed on human subjects where a
full text was available for data retrieval and written in English
were included (we did not contact any authors of the studies for
further information). All articles not meeting the inclusion criteria
as stated above were discarded. Moreover, editorials, letters to
the editor without original data, and reviews were excluded. In
addition, conference abstracts were excluded due to the lack of
details regarding data to assess the methodological quality.
The resulting items after database queries were checked for
duplicates and all titles and abstracts were screened to select all
the articles that met the inclusion criteria. Afterwards, the full
articles of the selected items were explored and reference lists,
citations, and previous review publications were searched to
identify other additional pertinent articles. Hereafter, 2 reviewers
(AB and APL) independently selected the studies and extracted
data from the full-text articles. Among other data (patients
characteristics, eventual medical treatment, adenomyosis, follow
up time, eventual APA recurrence and time at recurrence,
diagnosis of endometrial cancer or endometrial hyperplasia with
atypia during the follow up and at the time of diagnosis,
pregnancy desire, and successful pregnancy), patient treatment
time frame, geographic locations, and type of treatment were
retrieved from full text articles in order to avoid any possible
overlap of cases. When two or more studies used the same set of
patients or presented possible data overlap, only the one that was
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more recent and of better quality or with more detailed data was
included (if 2 articles presented different aspects of the same case
both articles were included and merged for the analysis). Any
discrepancy was addressed by a joint re-evaluation of the original
article. For the purpose of this study we stratified the conservative
surgical treatment in 2 categories: the classical inpatient blind
uterine dilatation, curettage, and polypectomy (DCP) including
also cervical polipectomy with forceps, that has been the
technique routinely used for many years to perform uterine
polypectomy; and operative histeroscopy (OH) (resection of the
polyp and biopsies under vision).
2.3. Assessment of methodological quality for included
studies
The quality of the literature has been evaluated through the use of
the CARE check list, in particular the presence of the following
items was assessed: patient information, clinical findings, the
presence of timeline information, diagnostic assessment, thera-
peutic intervention, follow-up, and outcomes.[10] We considered
the presence (+) of the information concerning a specific item to
be a sign of study with a low risk of bias, while the absence (–) of
an item was considered a sign of a study with a high risk of bias.
In some cases the item was classified as unclear (?) due to the
absence of sufficient information.
2.4. Data analysis
The analysis was performed using R (version 3.5.3 - R: A
language and environment for statistical computing. R Founda-
tion for Statistical Computing, Vienna, Austria), a P< .05 was
considered as significant.We calculated a summary statistic of the
prevalence of the outcomes taken into consideration. The I2 index
and the Cochran Q are used to evaluate heterogeneity between
studies. An index value of I2>50% and a value of P of Cochran
Q <0.10 were considered statistically significant signs of
heterogeneity. Where appropriate, the fixed or random effects
models were applied to calculate the synthesis estimate. In
addition case series with <5 cases and case reports were
aggregated for the analysis in forest plots. We also performed a
Kaplan–Meier analysis of cumulative events as previously
described.[7] The risk of bias assessment was not possible for
this study. This case report and case series meta-analysis is
exempt from ethical approval as the analysis involves only
already published and anonymized data.
3. Results
3.1. Search Results
The literature search flowchart is shown in Fig. 1. Overall 142
studies were found (Fig. 1) and 64 items were found to be not
eligible after reviewing the titles and the abstracts. Hence the
potentially eligible articles for this review were in total 78.
However, of these potentially eligible items for 2 articles it was
not possible to obtain the full text and for other 30 of these
articles inclusion criteria were not matched. In the Supplemental
List 1, http://links.lww.com/MD/E412, we show the included and
excluded studies. We finally selected 46 eligible articles (Fig. 1,
Supplemental Table 2, http://links.lww.com/MD/E411, and
Supplemental List 1, http://links.lww.com/MD/E412). All these
46 articles included in this review were case reports or case series
(only 10 articles comprise >5 cases).
3.2. Characteristics of the included studies
In our systematic review and meta-analysis, we included 46
observational studies that evaluated APA management in fertile
women. The main characteristics of these studies are reported in
Supplemental Table 2, http://links.lww.com/MD/E411. Of these
46 studies, 41 presented data for individual patients for a total of
129 cases (therapeutic management and follow up of 1 case was
presented in 2 different items a case report and a letter to the
Editor).[11,12] From another 6 studies with 202 cases, the data
were aggregated. In one study of 35 cases only some information
was extracted for the individual patients and this study was
considered in both the previous groups.[13] Therefore in total,
296 cases of APA were considered in this systematic review of the
literature.
Hereafter, we report the epidemiological and clinical features
extrapolated from the 127 cases with data for single patient.
Considering all 129 cases, the median age of fertile patients with
APA was 35 years (IQR 29–40), the BMI present for 45 patients
has a median value of 21kg/m2 (IQR 19–24). Based on the
reported data, the patients were mostly nulliparous (93.69% of
cases [104/111]) and with a history of infertility in 61.76% of
cases (21/34). Symptoms such as abnormal uterine bleeding, were
present in the majority of cases 76.12% (51/67).
All patients underwent primary surgical treatment: in most
cases conservative. In fact, 19/94 (20.2%) underwent hysterec-
tomy as first treatment after diagnosis (these were mainly old
patients and in any case in older studies). In 79.9% of cases a
conservative treatment has been proposed: blind techniques such
as polypectomy or cavity revision in 42.4% of cases and
operative hysteroscopy in 37% (34/92) but with an increase in
prevalence in more recent years. In addition, recently also
laparoscopic and lapatotomic conservative approach has been
proposed.[14,15] If a follow-up treatment was described for
recurrence, persistence or appearance of malignant lesions, 21
further hysterectomies were performed on 27 reported cases.
Post-surgery medical treatment was performed in 35/129 patients
(27.1%), in 33 cases (94.3%) was used medroxy progesterone
acetate (MPA) in varying patterns and doses, and in 2 cases
(5.7%) levonorgestrel medicated IUDs was used (in 1 case as
adjuvant therapy after first treatment and in 1 case after the
treatment of the second recurrence, none of these 2 cases had a
recurrence). In 2 cases was described >1 recurrence but for the
purpose of this study we considered only the first recurrence.
There were 5 studies only with aggregated data.[16–20] In these
case series the average age ranged between 38 and 56 years, with
a prevalence of nulliparous from 50% to 76% and a prevalence
of infertility from 15% to 35%. In these 5 studies the treatment
was prevalently conservative with a median of 76% of cases
treated in a conservative way, a minimum of 46%, and a
maximum of 86.4%.
3.3. Methodological quality assessment of the included
studies
Figure 2 and Supplemental Fig. 1A, http://links.lww.com/MD/
E399 and 1B, http://links.lww.com/MD/E400 highlight the
methodological quality of the articles included in this systematic
review and meta-analysis of the literature. Figure 2 presents a
summary of the evaluation of the items considered (the detail of
the evaluation of each item for the various studies is shown in
Supplemental Fig. 1A, http://links.lww.com/MD/E399 and 1B,
http://links.lww.com/MD/E400). Most items exceed 50% of
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positivity (the information is present and therefore we suppose a
low risk of bias). There was no information on conflict of interest
or no significant conflict of interest and any declared funding or
any funding by commercial agencies in the examined articles. The
publication bias could not be examined because it is not
applicable in this case.
4. Main results
4.1. Analysis of APA recurrences
The prevalence of APA relapses during follow-up was 44%
(CI.95 33–57%) on 198 cases analyzed (hysterectomies were
excluded because this outcome could not be evaluated) (Fig. 3A).
In Fig. 3A, that shows the forest plot of the APA recurrence
prevalence, there is an important heterogeneity in the data. To
justify this heterogeneity we considered the possibility of different
follow-up lengths and of different treatment approaches (blind
DCP vs operative hysteroscopy or use of “adjuvant” medical
therapy).
Therefore, an analysis was performed on the prevalence of
relapses according to the type of surgical treatment: DCP versus
resection under hysteroscopic vision (Fig. 3B and Supplemental
Fig. 2, http://links.lww.com/MD/E401). The prevalence of
relapses was lower if the conservative approach was that of
operative hysteroscopy rather than DCP. In an analysis by
stratifying between operative hysteroscopy versus DCP we
obtained a prevalence of relapses of 22% (CI.95 11–39%) in
cases treated with operative hysteroscopy versus 38% (CI.95 15–
67%) in cases treated with RCU/polypectomy (Fig. 3B).
Figure 1. Flow chart of the study.
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The analysis of the cumulative relapses on the 70 cases in which
it was possible to extrapolate the data on time-to-event follow-
up, we found that the risk increases with the increase of follow-up
length and at 10 years follow up was 59.54% (CI.95: 32.88–
75.61%) as high as in the studies with greater follow up such as
Longacre et al[19] or Chiyoda et al[13] (9–10 years) (Fig. 4A). It
was also statistically significant, during the follow-up, a greater
tendency to persist or to relapse in cases treated with DCP
compared with operative hysteroscopic treatment (P< .05)
(Fig. 4B).
Post-surgical progestogen medical treatment was used in a
small percentage of cases (26.8% of the total) and only in 5
studies.[4,15,21–23] The most common treatment was MPA.
Supplemental Fig. 3, http://links.lww.com/MD/E402 shows no
protective effect of MPA against recurrence in cases where
medical therapy was given after surgical treatment (26% vs
42%). In Fig. 4C relapses are not significantly different between
the MPA treated and non-treated cases (persistent cases were
excluded from this analysis). In only 2 cases the medicated IUD
with levonergestrel was used, and in one of these cases the IUD
was used after the appearance of the second recurrence.[15,23]
4.2. APA association with endometrial neoplasia and
atypical hyperplasia of the endometrium
The prevalence of the concomitant diagnosis or the diagnosis
during the follow-up of endometrial carcinoma was 16% (CI.95
9–29%) (Fig. 5A). The concomitant diagnosis alone of
endometrial carcinoma was 11% (CI.95 7–17%) (Fig. 5B).
The diagnosis of endometrial carcinoma during follow up was
14% (CI.95 7–26%) (Supplemental Fig. 5, http://links.lww.com/
MD/E404). There was a greater uniformity in the prevalence of
diagnosis of concomitant endometrial cancer among cases
undergoing operative hysteroscopy compared with blind treat-
ment (Supplemental Fig. 4, http://links.lww.com/MD/E403).
Evaluating the time course, the risk of diagnosis of endometrial
neoplasia was 59.91% (CI.95: 29.54–77.19%) at 14 years of
follow-up (Fig. 4D). The risk of cancer development during
Adverse and unanticipated events
Interv ention adherence and tolerability (How was this assessed?)
Important follow−up diagnostic and other test results
Clinician and patient−assessed outcomes (when appropriate)
Changes in intervention (with rationale)
Administration of intervention (such as dosage, strength, duration)
Types of intervention (such as pharmacologic, surgical, preventive, self−care)
Prognostic characteristics (such as staging in oncology) where applicable
Diagnostic reasoning including other diagnoses considered
Diagnostic challenges (such as access, financial, or cultural)
Diagnostic methods (such as PE, laboratory testing, imaging, surveys)
Important information from the patient's history with timeline information
Describe the relevant physical examination (PE) and other significant clinical findings
Relevant past interventions and their outcomes
Medical, family, and psychosocial history including relevant genetic information
Main concerns and symptoms of the patient
De−identified demographic information and other patient specific information




Figure 2. This chart on methodological quality shows the summary, considering all included studies in this meta-analysis, of each specific methodological quality
item.
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follow-up according to the cumulative analysis is statistically less
prevalent in cases treated primarily with operative hysteroscopic
surgery (10.56% new cumulative diagnosis at 5 years follow up;
CI.95 0–23.7%) than in cases treated with DCP (35.5% new
cumulative diagnosis at 5 years; CI.95 11.65–52.92%; P< .05)
(Fig. 4E).
Figure 4F, and Supplemental Figs. 6, http://links.lww.com/
MD/E405, 7, http://links.lww.com/MD/E406, and 8, http://links.
lww.com/MD/E408 show the association with endometrial
hyperplasia at the time of diagnosis or during follow-up. From
the literature analysis, the association with endometrial hyper-
plasia is 15%, the diagnosis is concomitant in 10% of cases and
occurs in follow-up in 11% of cases.
Concerning the cumulative analysis, the risk of diagnosis of
endometrial hyperplasia is 27.27% (CI.95: 0–50.15%) at 14
years of follow-up (Fig. 4F). No significant risk differences
were found considering different conservative surgical
management.
4.3. Pregnancy and adenomyiosis
Data on pregnancy outcome are reported in a low percentage of
studies. This depends above all on the fact that older studies
probably do not take into account the preservation of fertility,
while there is an absolute tendency in recent years. However,
pregnancy success is reported in 15/19 (79%) cases in which the
desire was expressed.
Finally, the association with adenomyosis is 18% (CI.95 8–
37%) (Supplemental Fig. 9, http://links.lww.com/MD/E409).
5. Discussion
APA is a rare condition and there were <500 cases among the
eligible studies for this systematic review. Therefore, it is difficult
to hypothesize in the future the feasibility of prospective or
randomized studies. There are case reports or case series and only
10 of these include>5 cases.[1,4,13,16–20,24–26] In the literature it is
stated a clear role for aggregated case reports to increase the
Study
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Figure 3. Summary forest plots of APA recurrences without considering the specific time-to-event follow-up. Panel A: Forest-plot of APA relapse prevalence. Case
series with <5 cases and individual case reports were aggregated. Panel B: In this forest-plot data were stratified by type of conservative treatment DCP versus
operative histeroscopy (for this analysis we did not stratified between aggregated and non-aggregated data). Case series with<5 cases and individual case reports
were aggregated. APA=atypical polypoid adenomyoma, DCP=dilatation, curettage and polypectomy.
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understanding of the trajectories of care in rare conditions.
Therefore, case reports meta-analysis are found to be an
important instrument in rare conditions where clinical studies
are not a practicable option.[6–8] Recently a meta-analyses from
case reports was claimed to have overlapping results with a meta-
analyses from clinical studies.[6–8]
The main result in our study was an APA relapse prevalence of
44% (CI.95 33–57%) and a significant lower prevalence in cases
treated with operative hysteroscopy (22%; CI.95 11–39%) than
in cases treated with DCP (38%; CI.95 15–67%). Also the risk of
cancer development during follow-up was significantly less in
cases treated with hysteroscopy (10.56% new cumulative
diagnosis at 5 years follow up; CI.95 0–23.7%) than DCP
(35.5% new cumulative diagnosis at 5 years; CI.95 11.65–
52.92%; P< .05). Pregnancy was observed in 79% cases in
which the desire was expressed.
The association of APA with adenomyosis was 18%, however
only in a minority of cases this information was reported in the
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Figure 4. Kaplan–Meier analysis based on the follow-up time in cases treated conservatively and in which the time-to-event data in the follow-up was available.
Panel A: Analysis considering the cumulative APA relapses. Panel B: Analysis considering cumulative APA recurrences and type of conservative treatment (DCP vs
operative histeroscopy Log-rank test P< .05). Panel C: Analysis considering cumulative APA relapses: in this plot cases treated with medical therapy after surgery
were compared with cases not treated with medical therapy after surgery (Log-rank test P< .05). Panel D: Analysis considering the cumulative endometrial cancer
diagnoses. Panel E: Analysis considering the cumulative endometrial cancer diagnoses: data were divided in 2 groups according to the type of conservative
treatment (DCP vs operative histeroscopy Log-rank test P< .05). Panel F: Analysis considering the diagnosis of cumulative endometrial hyperplasia. APA=atypical
polypoid adenomyoma, DCP=dilatation, curettage and polypectomy.
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studies, especially in older reports it was probably under-reported
due to limited diagnostic accuracy of non-invasive methods at
that time. The lesion mainly arises in fertile age with a median age
of 35 years, in infertile or otherwise nulliparous women.
Infertility is found in 61.76% of cases where information was
reported and nulliparous represent 93.69% of these cases.
The high prevalence of nulliparous women with subfertility
underlines the need to establish the safety of a conservative
treatment for a lesion considered benign but for which the data in
the literature show a risk of recurrence, and of association with
endometrial hyperplasia and cancer. Heatley[27] in a 2006 review
points to a risk of 30% relapse and a 9% risk of association with
cancer and hypeplasia. However, these data are older than 10
years ago, they do not seem to emerge from a systematic review of
the literature and above all do not take into account the most
recent treatment experiences in hysteroscopic surgery. This
systematic review of the literature and the meta-analysis
performed may be useful in the management of these rare
lesions in a particular patient setting as described above.
In 79.79% of cases a conservative treatment with preservation
of fertility has been proposed, while histerectomy is restricted to
cases in post-menopausal period (not included here) or as first line
treatment in older studies or in pre-menopausal age. The risk of
recurrence of APA in this meta-analysis is 44%, with a
conspicuous heterogeneity between studies and peaks, especially
in the larger case series that evidently include longer recruitment
and follow-up periods. And in this meta-analysis the time-to-
event analysis showed a 10 years cumulative recurrence of
59.54%.
The hypothesis underlying this work, however, is linked to the
fact that different frequencies of relapse depend on the type of
treatment performed. Already Matsumoto et al[18] showed in his
Study
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Figure 5. Summary forest plots of endometrial cancer diagnosis. Panel A: Forest-plot of the prevalence of concomitant or during the follow-up diagnosis of
associated endometrial neoplasia. Case series with <5 cases and individual case reports were aggregated. Panel B: Forest-plot of the prevalence of concomitant
diagnosis of associated endometrial neoplasia. The time-to-event follow-up was not considered in this analysis. Case series with <5 cases and individual case
reports were aggregated.
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case series a risk of recurrence of 36% in patients treated with
DCP and 10% in patients undergoing hysteroscopic removal.
Our meta-analysis confirmed this difference by reporting a risk of
persistence/recurrence of 38% versus 22% respectively in the
case of DCP or hysteroscopic treatment (Fig. 3B). Confirmed also
by the time-to-event analysis (Fig. 4B).
Medical treatmentwithprogesteroneas adjuvantmedical therapy
after surgery, although reported in 25% of the total treated cases,
appears to imply a non-significant difference in the cumulative
relapses considering the time to event analysis (see Supplemental Fig.
3, http://links.lww.com/MD/E402 and Fig. 4C, http://links.lww.
com/MD/E403). In all cases, considered in these analysis (Supple-
mental Fig. 3, http://links.lww.com/MD/E402 and Fig. 4C, http://
links.lww.com/MD/E403), the drug used was MPA. In 2 cases, 1
after first treatment and 1 after the appearance of the second
recurrence, intrauterine device (IUD) medicated with levonergestrel
was used, in both no recurrencewas described.[15,23] In addition, the
group of Nomura published recently a second article describing the
same cases of a previous case series considered in this meta-analysis,
and showing that continuing in 5 cases with progestogens treatment
after MPA treatment will reduce the incidence of recurrences.[4,28]
Considering what emerges from the literature, it can be concluded
thatmedical therapydoesnot entail particularadvantages, especially
when using a hysteroscopic eradication treatment, unless it is
associated with cancer or endometrial hyperplasia where the benefit
of MPA treatment has already been described.
In particular, we want to point out some interesting
considerations about follow-up: it was noted that recurrences
occur even after several years, at 10 years the cumulative
recurrences shows a 59.54% risk (CI.95: 31.88–75.61%)
comparable to the studies with greater follow up periods such
as Longacre et al[19] or Chyoda et al[13] (9–10 years). In addition
we observed a significantly higher risk of persistence/relapse in
case of DCP than in operative hysteroscopy (P< .05).
This certainly imposes the need to monitor these patients
considering also the specific category of patients seeking for
pregnancy. It is not possible, of course, to define a precise follow-up
scheme based on strong evidence base medicine, in fact there are
different disparities in this literature. However, it is possible to
envisage closer checks initiallyandsubsequently less intensive, using
ultrasound examinations followed, if in suspicion of recurrence by
hysteroscopy and biopsy or by directly performing hysteroscopy
and biopsy according to the local organizational setting.
The association with endometrial cancer was 16% (CI.95 9–
29%), concurrent with APA diagnosis in 12% and during follow-
up in 14%. Respectively, the association with endometrial
hyperplasia was 15% (total), 10% (concomitant with APA
diagnosis), and 11% (during follow up). In our analysis the time-
to-event cumulative occurrences were also high (endometrial
cancer 59.91% at 14 years of follow-up—hyperplasia 27.27% at
14 years of follow-up). These prevalences are higher than those
shown by Heatley.[27] The prevalence found in our meta-analysis
may also be superior in consideration of the type of treatment,
where treatment by DCP often does not allow a good differential
diagnosis in comparison to hysteroscopy (at the time of Heatley
was more commons DCP than operative hysteroscopy). This
could be also justified by the fact that in our analysis the
prevalence uniformity of endometrial hyperplasia diagnosis was
higher in hysteroscopic cases than DCP cases because the higher
accuracy of hysteroscopic diagnosis.
The pathogenesis of endometrial carcinoma associated to APA
is unknown: it is not clear if the endometrial cancer is developing
in the context of APA or in the remaining adjacent or distant
endometrium. Bakalianou et al[29] describes one case of 36-year-
old patient with presence of neoplasm foci within APA specimen,
as well as Mittal et al,[30] Sonoyama et al,[31] and Nejković
et al.[32] Evaluating the time course, the risk of diagnosis of
endometrial neoplasia is 59.91% (CI.95: 29.54–77.19%) at
14 years of follow-up. The risk of cancer development during
follow-up according to the cumulative analysis is statistically
reduced in cases treated primarily with hysteroscopic surgery
(P< .05) than those treated with DCP. These data highlight the
need for long-term follow-up. Furthermore, these same data
invite us to reflect on what should be the treatment of the patient
once the reproductive process has ended, or rather if there is any
indication to remove the uterus after pregnancy or in case of
recurrence. Despite this kind of management with histerectomy at
the end of reproductive age does not change the long-time
prognosis of these patients, it can have psychological repercus-
sions.
Finally, the studies considering the pregnancy outcome are
scarce, in fact pregnancy outcome is under-reported especially in
less recent studies. Our meta-analysis shows among patients
undergone to conservative surgical treatment a successful
pregnancy in 78% of cases where there is a clear desire for
offspring, however with a variability related to woman age or
associated pathologies, or use of medically assisted reproduction
(that could be a choice to shorten the time for having a pregnancy
in a population at high risk of having recurrences or new
endometrial cancer diagnosis).[4]
In summary APA is a rare lesion, which occurs predominantly
in fertile age and in association with infertility and nulliparity.
Conservative treatment is indicated in these patients. The data
emerged from this review suggests that conservative treatment
performed by operative histeroscopy (lesion resection and
endometrial biopsies adjacent to the lesion and at a distance)
is the optimal choice because it optimizes fertility preservation, it
lowers the risk of recurrences and improve the accuracy of
concomitant carcinoma or hyperplasia diagnosis. The medical
treatment with MPA, following conservative surgery, does not
appear to be beneficial in the treated cases, except in the presence
of a diagnosis of carcinoma or endometrial hyperplasia.
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